Metsera Inc. (NASDAQ:MTSR - Get Free Report)'s share price was down 4.1% during mid-day trading on Wednesday . The stock traded as low as $37.52 and last traded at $37.83. Approximately 48,370 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 896,253 shares. The stock had previously closed at $39.45.
Wall Street Analyst Weigh In
Several research firms have issued reports on MTSR. Guggenheim boosted their price objective on Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Wells Fargo & Company initiated coverage on shares of Metsera in a research note on Friday, June 20th. They issued an "overweight" rating and a $65.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Metsera presently has an average rating of "Buy" and an average target price of $55.00.
Check Out Our Latest Research Report on Metsera
Metsera Stock Up 2.1%
The business has a fifty day moving average price of $31.84.
Metsera (NASDAQ:MTSR - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($1.03) earnings per share for the quarter.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp bought a new stake in Metsera in the 1st quarter valued at $884,000. New York State Common Retirement Fund bought a new stake in shares of Metsera during the 1st quarter valued at $131,000. Alphabet Inc. bought a new stake in shares of Metsera during the 1st quarter valued at $135,059,000. Massachusetts Financial Services Co. MA acquired a new position in shares of Metsera during the 1st quarter worth $13,111,000. Finally, Jennison Associates LLC acquired a new position in shares of Metsera during the 1st quarter worth $9,679,000.
Metsera Company Profile
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Stories
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
